These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Patients with multiple risk factors require especially vigilant monitoring
Taken together, evidence from neuroscience, human research, and clinical practice suggests meaningful overlap between obesity and addiction-related mechanisms. Lorenzo Leggio, MD, PhD, clinical director, National Institute on Drug Abuse, Bethesda, Md
Some people report mild discomfort when they first introduce this powerful molecule into their routine
GLP-1 is a natural hormone produced in the gut and released after you eat carbohydrates or fats